Literature DB >> 1484472

Treatment of chronic nonvalvular atrial fibrillation in the elderly: a decision analysis.

I G Naglie1, A S Detsky.   

Abstract

The objective of the study was to determine the preferred treatment strategy for elderly patients with chronic nonvalvular atrial fibrillation (CNVAF). A Markov decision-analytic model was used to compare three treatment strategies for CNVAF: 1) warfarin; 2) aspirin; and 3) no treatment. Five-year quality-adjusted life years (QALYs) were calculated for male and female cohorts aged 70 and 75 years. In the baseline analysis (effectiveness of warfarin = 0.70, effectiveness of aspirin = 0.45, utility of warfarin = 0.99, and utility of aspirin = 0.999) the quality-adjusted survival rates for 70-year-old males were 4.03 QALYs on warfarin, 4.02 QALYs on aspirin, and 3.95 QALYs on no treatment. Results were similar for all age and sex cohorts. Sensitivity analyses revealed that the results were very sensitive to the effectiveness of aspirin and the disutility of warfarin. The authors conclude that the optimal strategy for the treatment of CNVAF in elderly patients varies with the disutility assigned to warfarin therapy and the effectiveness value for aspirin therapy.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1484472     DOI: 10.1177/0272989X9201200401

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  10 in total

1.  Can computerised decision support systems deliver improved quality in primary care?. Interview by Abi Berger.

Authors:  B C Delaney; D A Fitzmaurice; A Riaz; F D Hobbs
Journal:  BMJ       Date:  1999-11-13

2.  The cost-effectiveness of different management strategies for patients on chronic warfarin therapy.

Authors:  J E Lafata; S A Martin; S Kaatz; R E Ward
Journal:  J Gen Intern Med       Date:  2000-01       Impact factor: 5.128

3.  Cerebral Sinovenous Thrombosis.

Authors:  Ferdinando S. Buonanno
Journal:  Curr Treat Options Cardiovasc Med       Date:  2001-10

4.  Aspirin for primary prevention of cardiovascular events.

Authors:  F A Augustovski; S B Cantor; C T Thach; S J Spann
Journal:  J Gen Intern Med       Date:  1998-12       Impact factor: 5.128

5.  Preferences for oral anticoagulants in atrial fibrillation: a best-best discrete choice experiment.

Authors:  Peter Ghijben; Emily Lancsar; Silva Zavarsek
Journal:  Pharmacoeconomics       Date:  2014-11       Impact factor: 4.981

6.  Quantifying the utility of taking pills for preventing adverse health outcomes: a cross-sectional survey.

Authors:  Robert Hutchins; Michael P Pignone; Stacey L Sheridan; Anthony J Viera
Journal:  BMJ Open       Date:  2015-05-11       Impact factor: 2.692

7.  Cost-effectiveness of aspirin adjuvant therapy in early stage colorectal cancer in older patients.

Authors:  Swee Sung Soon; Whay-Kuang Chia; Mun-ling Sarah Chan; Gwo Fuang Ho; Xiao Jian; Yan Hong Deng; Chuen-Seng Tan; Atul Sharma; Eva Segelov; Shaesta Mehta; Raghib Ali; Han-Chong Toh; Hwee-Lin Wee
Journal:  PLoS One       Date:  2014-09-24       Impact factor: 3.240

Review 8.  Health-related quality of life impact of minor and major bleeding events during dual antiplatelet therapy: a systematic literature review and patient preference elicitation study.

Authors:  Brett Doble; Maria Pufulete; Jessica M Harris; Tom Johnson; Daniel Lasserson; Barnaby C Reeves; Sarah Wordsworth
Journal:  Health Qual Life Outcomes       Date:  2018-09-20       Impact factor: 3.186

9.  Stroke of antiplatelet and anticoagulant therapy in patients with coronary artery disease: a meta-analysis of randomized controlled trials.

Authors:  Qiao Yu Shao; Zhi Jian Wang; Xiao Teng Ma; Xu Ze Lin; Liu Pan; Yu Jie Zhou
Journal:  BMC Cardiovasc Disord       Date:  2021-12-01       Impact factor: 2.298

10.  Values and preferences in oral anticoagulation in patients with atrial fibrillation, physicians' and patients' perspectives: protocol for a two-phase study.

Authors:  Pablo Alonso-Coello; Victor M Montori; Ivan Solà; Holger J Schünemann; Philipe Devereaux; Cathy Charles; Mercè Roura; M Gloria Díaz; Juan Carlos Souto; Rafael Alonso; Sven Oliver; Rafael Ruiz; Blanca Coll-Vinent; Ana Isabel Diez; Ignasi Gich; Gordon Guyatt
Journal:  BMC Health Serv Res       Date:  2008-10-27       Impact factor: 2.655

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.